How Can Sponsors Partner with CureNet?
CureNet combines the agility of independent research sites with the operational sophistication of a contract research organization (CRO), providing sponsors with a unique partnership model that ensures both quality and speed.
Key Advantages
Premier Allergy & Immunology Expertise
CureNet represents leading physician-investigators in allergy, asthma, immunology, dermatology, and immunotherapy—providing access to highly phenotyped patient populations across multiple states and diverse demographics.
Streamlined Study Activation
Centralized contracting, budgeting, and IRB submissions via a Master Services Agreement (MSA) framework enable faster site start-up and consistent sponsor communication.
Quality Standardization & Regulatory Support
Comprehensive SOPs, standardized documentation, and dedicated quality teams ensure ICH-GCP compliance, reproducibility, and audit readiness across all sites.
Integrated Technology Platform
CureNet sites utilize unified systems for eISF, CTMS, remote monitoring, and data management, enhancing transparency and reducing administrative burden for sponsors.
Patient Recruitment & Retention Excellence
Our physician-led practices maintain active patient panels, ensuring rapid recruitment and above-average retention rates in therapeutic areas with unmet needs.
Education & Visibility
CureNet hosts an Annual Research & Innovation Conference, showcasing advances in immunology, clinical research methodology, and sponsor-collaborative findings.
Sponsors are invited to participate, present, and engage directly with physician investigators and site leaders.
Partnership Opportunities
Master Service Agreements
Accelerates execution of multiple clinical trials through a single, standardized agreement—eliminating redundancy, aligning terms, and enabling faster activation.
Preferred Partnership
Establishes CureNet as a preferred research partner with tiered access to highly qualified sites, consistent feasibility turnaround, and performance metrics tracking.
Trial Specific Agreements
Seamless integration for Phase I–IV trials, post-marketing surveillance, real-world evidence (RWE), and investigator-initiated studies (IIS).
Joint Collaborations
Opportunities to co-develop registries, real-world databases, and biomarker research platforms in allergic and immunologic diseases.